Tacrolimus Market Regional
Analysis
North America Tacrolimus
Market is expected to dominate over the forecast period. Presence of
leading manufacturers as well as high number of organ transplant procedures is
expected to support global tacrolimus market growth. Regional generic
manufacturers are focusing on providing generic version of tacrolimus
formulations in developed as well emerging economies. For instance, Strides
Arcolab received the U.S. Food & Drug Administration (FDA) approval for
tacrolimus capsules to be used as immuno-suppressant in 2014. Sandoz launched
Tacrolimus, a generic version of Astellas’s PROGRAF (tacrolimus) in Japan, in
2015. Moreover, The European Medicines Agency’s (EMA) Committee for Medicinal
Products for Human Use (CHMP) recommended granting marketing authorization for
tacrolimus’ generic, Tacforius in 2017. These factors have supported the global
tacrolimus market growth.
Tacrolimus is used as an
immunosuppressant mainly after organ transplant procedures to prevent organ
rejection. Tacrolimus inhibits the activation of serine-threonine phosphatase,
calcineurin, in T lymphocytes. This suppresses T lymphocyte activation and the
subsequent generation of cytotoxic lymphocytes, thereby suppressing processes
leading to organ rejection. Tacrolimus is primary immunosuppression drug used
in kidney and liver transplant patients. Organ transplanted patients often
require lifelong treatment with immunosuppressant. Major applications of this
includes in cardiac transplant rejection, liver transplant rejection, kidney
transplant rejection, and lung transplant immunosuppression treatment.
Tacrolimus is available in various dosage forms such as tablets, capsules, and
injections.
* The sample copy includes:
Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report
Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2298
Tacrolimus Market Drivers
Tacrolimus is majorly used as an
immunosuppressant after organ transplant procedures. Advancement in organ
transplant procedures is a major factor expected to increase the number of
organ transplants, which in turn is expected to boost global tacrolimus market
growth over the forecast period. For instance, new methods are being researched
to match more donor organs with patients such as stem cell studies, trophic
factor studies, and natural models. As the need for organ transplantation
increases and the waiting list continues to grow, successful utilization and
transplantation of as many available donor organs as possible has become
important. According to Organ Procurement and Transplantation Network (OPTN)
117,000+ number of men, women, and children are on the national transplant
waiting list as of July 2017 in the U.S. and 17,155 organ transplants are done
so far in 2017.
Moreover, according to National
Kidney Foundation as of 2016, 121,678 people are waiting for lifesaving organ
transplants in the U.S., of which 100,791 people are waiting for kidney
transplants. Moreover, organ transplantation procedures have evolved with
increase in feasibility and better understanding of immunology, which has allowed
for improved matching rates for organs and patients after transplants. This is
expected to result in increasing number of organ transplants which is expected
to support the global tacrolimus market growth over the forecast period.
Browse Research Report:
https://www.coherentmarketinsights.com/ongoing-insight/tacrolimus-market-2298
Certain side effects (malignancy,
Psychosis, and others) of tacrolimus, although not significant, may hamper the
global tacrolimus market growth. However, major growth limiting factor is
expected to be significant gap between demand and supply of transplant organs,
which indirectly could affect the global tacrolimus market growth.
Tacrolimus Market Key Players
Key players operating in the
global tacrolimus market include GlaxoSmithKline Plc, Abbott Laboratories,
Novartis International AG, Mylan N.V., Astellas Pharma, Inc., Takeda
Pharmaceuticals Company Ltd, Senju Pharmaceutical Co. Ltd., Guike
Pharmaceutical Co. Ltd., DR. Reddy’s Laboratories Ltd., and Glenmark
Pharmaceuticals Ltd.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2298
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment